Plasma total homocysteine levels in stroke patients screened for the vitamin intervention for stroke prevention clinical trial in the era of folate fortification

Neuroepidemiology

Volumn 26, Issue 1, 2005, Pages 45-51

  Lutsep, Helmi L ^a   Campbell, Stephen ^b   Chambless, Lloyd E ^b   Howard, Virginia J ^c   Toole, James F ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d WAKE FOREST UNIVERSITY   (United States)

Author keywords

Folic acid; Homocysteine; Stroke

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN;

ADULT; AGED; ARTICLE; CANADA; CLINICAL TRIAL; DEMOGRAPHY; DIET RESTRICTION; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT; PROPHYLAXIS; RACE; SAMPLE; SCREENING; STROKE; UNITED STATES; VITAMIN SUPPLEMENTATION;

ADULT; AGED; CANADA; CEREBROVASCULAR ACCIDENT; FASTING; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; UNITED STATES; VITAMINS;

EID: 29144496957     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089238     Document Type: Article

References (28)

1. Food standards: amendment of standard of identity for enriched grain products to require addition of folic acid. Federal Register 1996;61:8781-8797.
2. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-1454.
3. Regulations amending the Food and Drug Regulations (1066). Canada Gazette 1997;131:3702-3737.
4. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698.
5. Kang SS, Wong PW, Norusis M: Homocysteinemia due to folate deficiency. Metabolism 1987;36:458-462.
6. Coull BM, Malinow MR, Beamer N, Sexton G, Nordt F, de Garmo P: Elevated plasma homocyst(e)ine concentrations as a possible independent risk factor for stroke. Stroke 1990;21:572-576.
7. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ: A prospective study of plasma homocysteine and risk for ischemic stroke. Stroke 1994;25:1924-1930.
8. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057.
9. Eikelboom JW, Lonn E, Genest JR, Hankey G, Yusuf S: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-375.
10. The Homocysteine Studies Collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2222.
11. 6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998;5:249-255.
12. Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, Toole JF: Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. Neuroepidemiology 2001;20:16-25.
13. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang C-H, Stampfer M: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
14. Lawrence JH, Petitti DB, Watkins M, Umekubo MA: Trends in serum folate after food fortification. Lancet 1999;354:915-916.
15. Carlsson CM, Stein JH: Clinical trials testing the homocysteine hypothesis (letter). Ann Intern Med 2002;137:295-296.
16. Bostom AG, Selhub J, Jacques PF, Rosenberg IH: Power shortage: clinical trials testing the 'homocysteine hypothesis' against a background of folic acid-fortified cereal grain flour. Ann Intern Med 2001;135:133-137.
17. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB: Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995;26:795-800.
18. Howard VJ, Sides EG, Newman GC, Cohen SN, Howard G, Malinow MR, Toole JF, for the Stability of Plasma Homocyst(e)ine in Acute Stroke Patients (SHASP) Study Investigators: Changes in plasma homocyst(e)ine in acute phase after stroke. Stroke 2002;33:473-478.
19. Smolin LA, Schneider JA: Measurement of total plasma cysteamine using high-performance liquid chromatography with electrochemical detection. Anal Biochem 1988;168:374-379.
20. Malinow MR, Kang SS, Taylor LM, Wong PW, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B: Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989;79:1180-1188.
21. Malinow MR, Sexton G, Averbuch M, Grossman M, Wilson D, Upson BS: Homocyst(e)ine in daily practice: levels in coronary artery disease. Coronary Artery Disease 1990;1:215-220.
22. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202.
23. Yang Q, Friedman JM, Botto LD: Improvement in cardiovascular and stroke mortality after flour fortification with folic acid in the United States. 44th Annu Conf Cardiovasc Dis Epidemiol Prevent, San Francisco, 2004.
24. 6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. Stroke 2003;34:e51-e54.
25. Hankey GJ, Eikelboom JW, Loh K, Yi Q, Tang M, Pizzi J, Klijn CJ, Dusitanond P, van Bockxmeer F, Baker RI, Jamrozik K, for the VITATOPS Trial Collaborative Group: Is there really a power shortage in clinical trials testing the 'homocysteine hypothesis'? Preliminary results from the VITAmins TO Prevent Stroke (VITATOPS) Trial (abstract). Stroke 2004;35:254.
26. Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, Wright JD, Johnson C: Serum total homocysteine concentrations in the third national health and nutrition survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentration. Ann Intern Med 1999;131:331-339.
27. Giles WH, Kittner SJ, Croft JB, Wozniak MA, Wityk RJ, Stern BJ, Sloan MA, Price TR, McCarter RJ, Macko RF, Johnson CJ, Feeser BR, Earley CJ, Buchholz DW, Stolley PD: Distribution and correlates of elevated total homocyst(e)ine: the Stroke Prevention in Young Women study. Ann Epidemiol 1999;9:307-313.
28. Kittner SJ, Giles WH, Macko RF, Hebel JR, Wozniak MA, Wityk RJ, Stolley PD, Stern BJ, Sloan MA, Sherwin R, Price TR, McCarter RJ, Johnson CJ, Earley CJ, Buchholz DW, Malinow MR: Homocyst(e)ine and risk of cerebral infarction in a biracial population: the Stroke Prevention in Young Women study. Stroke 1999;30:1554-1560.